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Abstract
Introduction We describe the natural history of patients with a
Zellweger spectrum disorder (ZSD) surviving into adulthood.
Methods Retrospective cohort study in patients with a genet-
ically confirmed ZSD.
Results All patients (n=19; aged 16–35 years) had a follow-
up period of 1–24.4 years (mean 16 years). Seven patients had
a progressive disease course, while 12 remained clinically
stable during follow-up. Disease progression usually mani-
fests in adolescence as a gait disorder, caused by central and/
or peripheral nervous system involvement. Nine were capable
of living a partly independent life with supported employ-
ment. Systematic MRI review revealed T2 hyperintense white
matter abnormalities in the hilus of the dentate nucleus and/or
peridentate region in nine out of 16 patients. Biochemical
analyses in blood showed abnormal peroxisomal biomarkers
in all patients in infancy and childhood, whereas in
adolescence/adulthood we observed normalization of some
metabolites.
Conclusions The patients described here represent a distinct
subgroup within the ZSDs who survive into adulthood. Most
remain stable over many years. Disease progression may oc-
cur and is mainly due to cerebral and cerebellar white matter






VLCFAs very long-chain fatty acids
ZSDs Zellweger spectrum disorders
Introduction
Zellweger spectrum disorders (ZSDs, OMIM #601539) con-
stitute a subgroup of the peroxisome biogenesis disorders and
represent a clinical continuum from severe to relatively milder
phenotypes. ZSDs are caused by pathogenic mutations in at
least 13 different PEX genes, encoding peroxins. Generally,
there is genotype-phenotype correlation (Rosewich et al 2005)
(Moser 1999). Patients with the severe phenotype present in
the neonatal period with failure to thrive, jaundice, hypotonia
and dysmorphic features (Weller et al 2003) and high mortal-
ity within the first year of life. This severe phenotype was
described as Zellweger syndrome (Bowen et al 1964).
Patients with a milder phenotype display a more variable
symptomatology and age of presentation, but the onset is usu-
ally in early childhood. The most common presenting signs
are developmental delay, with visual loss from retinal degen-
eration, sensorineural hearing loss and liver disease
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(Baumgartner et al 1998). Themajority of ZSD patients with a
mild phenotype have normal MRI findings during childhood,
but ultimately develop leukoencephalopathy later in life (Poll-
The and Gärtner 2012).
Definitive diagnosis requires laboratory investigations to
assess peroxisomal functions, and confirmation by enzymatic
analysis in fibroblasts, and/or PEX gene mutation studies.
Only limited data are available on the phenotype and nat-
ural history in adults with ZSDs (Rosewich et al 2005)
(Mignarri et al 2012) (Matsui et al 2013) (Raas-Rothschild
et al 2002) (Régal et al 2010). To improve the accuracy of
clinical diagnosis and to enable comparison of future evalua-
tions of therapeutic interventions, we describe the natural his-




Retrospective clinical and laboratory data were collected from
19 ZSD patients. The diagnosis was confirmed by biochemi-
cal and molecular testing. Clinical and biochemical data were
collected at many time points between 1991 and 2014. All
patients were seen in the Academic Medical Centre in
Amsterdam and examined by the authors (ME, PGB, or
BTPT). Some data from patients 1, 3–6, 8, 13–14, 16–18
(Poll-The et al 2004) and patient 4 (Ebberink et al 2012) were
reported previously. Age at diagnosis was defined as biochem-
ically confirmed diagnosis, and not the onset of symptoms.
Hearing and visual assessment
Objective methods (brainstem audiometry evoked response
and visually evoked potentials) and subjective methods
(free-field audiometry and Snellen chart, with 1.0 scored as
normal vision (Peters 1961)) were used to asses hearing and
visual impairment.
Imaging
A total of 39 MRI studies of the brain were performed in 16
patients. The studies were performed on a 1.5 T MR scanner
using the following sequences: axial, sagittal and coronal
spin-echo T1-weighted, T2-weighted and axial fluid-
attenuated inversion recovery image. The first MRI scans of
patients 8, 9, and 16–19, the first and secondMRI’s of patients
1, 3, and 5 and the fourth MRI of patient 6 were described
earlier (Barth et al 2004). Liver cirrhosis was diagnosed using
a Fibroscan, as described previously (Foucher et al 2006).
Laboratory tests
To establish whether a patient is affected by a ZSD
several peroxisomal metabolites, reflecting the in vivo
function of peroxisomes, were determined in blood, in-
cluding levels of VLCFA, phytanic and pristanic acid
(Vreken et al 1998), pipecolic acid (Rashed et al
2001) and bile acids (Bootsma et al 1999). In erythro-
cytes, plasmalogen (C16:0- and C18:0-dimethyl acetal)
levels were measured (Dacremont and Vincent 1995)
and levels of oxalic acid and glycolic acids were deter-
mined in urine spots and corrected for creatinine excre-
tion (Wolthers and Hayer 1982). A total of 332 bio-
chemical analyses were performed in plasma, ranging
from two (patient 4) to 43 (patient 18) tests per patient.
Adrenal insufficiency was diagnosed by means of an
adrenocorticotropic hormone stimulation (Synacthen)
test (Berendse et al 2014).
Several peroxisomal parameters were studied in cultured
skin fibroblasts including, catalase immunofluorescence mi-
croscopy (Wanders et al 1989), VLCFA profile (Dacremont
et al 1995), peroxisomal alpha- and beta-oxidation activity
(Wanders et al 1995a) and dihydroxyacetonephosphate-
acyltransferase (DHAPAT) activity (Wanders et al 1995b).
Mutation analysis
Complementation analysis in cultured skin fibroblasts was
used to determine the defective PEX gene, followed by
Sanger sequencing on genomic DNA (Ebberink et al 2011).
Statistical analysis
Mann–Whitney U tests were performed using the IBM
Statistical package for the Social Sciences (SPSS) software
version 20 (IBM, U.S.A.).
Standard protocol approvals, registrations and patient
consents
For this project the IRB issued a waiver since the study is
retrospective and only anonymized data was used. Written
informed consent was obtained from the parents of all the
patients, and authorization for disclosure of recognizable per-
sons in photographs for publication were obtained.
Results
The detailed clinical characteristics of the 19 patients from 16
families are summarized in Tables 1 and 2. All patients, nine
females and ten males, were of Caucasian background and no
parental consanguinity was reported. To obtain a framework
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for comparing the severity of the neurologic disorder with the
MRI findings and biochemical abnormalities we delineated
two broad categories on the basis of the degree of communi-
cation. Patients in group 1 (patients 1–12) were able to com-
municate with structured grammatical speech and patients in
group 2 (patients 13–19) had no structured speech. Age at
diagnosis varied between 7 days and 31 years (mean group
1: 7.6 years, group 2: 1.2 years). The diagnosis of patients 3
and 16 was at an early age because they had an affected older
sibling. In two other patients (2 and 4) there was a significant
delay before diagnosis, due to normal peroxisomal metabo-
lites in plasma and a clinical presentation atypical for a ZSD
(Ebberink et al 2012).
We obtained information about clinical features, biochem-
ical profile, education, current level of social functioning and
help required for activities of daily living.
Clinical features
During infancy, seven of the 19 patients had prolonged neo-
natal jaundice, four presented with hypotonia, five with failure
to thrive, 12 had a visual handicap due to retinal degeneration
a n d e i g h t p a t i e n t s p r e s e n t e d w i t h h e a r i n g
impairment (Table 1). During childhood, all patients had a
moderate to severe developmental delay as well as visual
and hearing loss. Current ages ranged from 16 to 35 years
(mean 22.5 years). Patient 18 died from liver failure at
18 years. At last follow-up, all patients had nyctalopia and
retinopathy, caused by retinitis pigmentosa in 16/19. Visual
acuity ranged from 4 to 33 % (mean 14 %) with 100 % being
normal vision and 5 % defined as legally blind in Europe
(Kocur and Resnikoff 2002). The visual impairment was pro-
gressive in four and stable in 14 patients. All had gross sen-
sorineural hearing deficits, ranging from a loss of 60 dB to
110 dB and 17 patients (except patients 15 and 18) used hear-
ing aids with clinical benefit. Ambulation ranged from run-
ning (11/19) to walking unsupported (3/19), walking with
support (2/19) and the ability to sit unsupported (3/19).
Patient 5 had normal motor function during childhood.
However, since the age of 15 years he lost the ability to walk
independently due to progressive cerebellar ataxia and weak-
ness caused by peripheral neuropathy. At the age of 21 he
developed pyramidal signs and became completely
wheelchair-bound at 23 years. Patient 18 was able to walk
independently at 4 years of age, but at the age of 14 years
she developed progressive cerebellar and sensory ataxia and
lost independent ambulation.
Specific findings included cerebellar signs in 9/19, pyrami-
dal signs in 5/19 and signs of peripheral neuropathy in 11/19
patients (Table 2). The peripheral neuropathy could only be
confirmed by nerve conduction studies in two patients (5 and
10), due to reluctance of the parents to allow latter studies. In
these two patients the neuropathy was classified as a
demyelinating neuropathy, according to established criteria with
a motor conduction velocity below 41 ms in the median nerve
and 35 ms in the peroneal nerve (Van Asseldonk et al 2005).
Overall, seven had progressive neurological symptoms (mainly
worsening of the gait disorder) and 12 were stable at most recent
follow-up. Epilepsy was not seen in any of the patients.
Non-neurological findings included splenomegaly, hepato-
megaly, renal pelvic stones and adrenal insufficiency in one
patient and liver cirrhosis in 3/19. All patients had enamel
hypoplasia.
Activities of daily living
Of the 19 patients, six lived in assisted-care facilities (Table 1),
of whom patients 15 and 17–18 lived in a round the clock care
facility and were completely dependent on others (i.e., nursing
home). The remaining three were self-supporting with respect
to daily life activities, albeit under supervision. The other 13
patients lived with their parents, with or without continuous
supervision. Of these patients, only patients 13 and 14 were
not able to feed themselves independently. All patients except
for patient 11 had a minor to severe gait disorder, limiting their
physical mobility. Cognition varied widely from normal cog-
nitive abilities in patient 11, to moderate or severe intellectual
disability in most.
MRI findings
Cerebral MRI scans were available from 16 patients, with
follow-up in 10 (Table 3). T2-weighted MR images showed
progressive hyperintense white matter changes in the cerebral
hemispheres in 4/16. These were located around the
supratentorial ventricular system merging with surrounding
normal white matter without sharp demarcation. Patient 6
(Fig. 1) had additional lesions in the corpus callosum and in
the posterior limbs of the internal capsules. Follow-up images
showed progressive central cerebellar white matter changes
on T2-weighted images between 11 and 22 years.
Furthermore, 8/16 patients had T2 hyperintensities in the areas
surrounding the cerebellar dentate nuclei, which was progres-
sive in 3 (patients 3, 5–6). T2-hyperintensity in the cerebellar
white matter was seen in 6 patients, and was progressive in
one (patient 6). Two patients (16, 18) had supratentorial ven-
tricular dilatation and 6/16 presented with cerebellar cortical
atrophy, of whom 3 patients (3, 16, 18) showed concomitant
supratentorial cortical atrophy.
Laboratory tests
Detailed individual biochemical profiles, during the time of
diagnosis and last follow-up, are described in Tables 4 and 5.
At the last available measurement the most important abnor-
malities in plasma included elevated levels of C26:0 (16/19
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patients), pipecolic acid (10/19 patients), DHCA (9/19 pa-
tients) and THCA (6/19 patients). There were two patients
(patients 2 and 11) with only one mildly abnormal peroxisom-
al biomarker in plasma and erythrocytes. Compared with the
biochemical results at time of diagnosis, we observed a de-
cline in the levels of DHCA and THCA (15/19 patients), C29-
dicarboxylic acid (13/14 patients) and pipecolic acid (10/19
patients), and in some patients even a complete normalization
(patients 6–11, 14, 19).
In general, patients had reduced levels of fat soluble vita-
mins (A, D, E and K) and a coagulopathy, due to a combined
vitamin K malabsorption and liver dysfunction. The majority
of patients had a low-phytanic acid and low-fat diet and 14
patients received vitamin A, D, E and K supplementation.
Discussion
The ZSDs have long been considered lethal in infancy or early
childhood, based on the original description of Zellweger syn-
drome (Bowen et al 1964). In this retrospective study, we
describe a large cohort of patients with a ZSD and show that
the natural history is highly variable with a distinct subgroup
surviving well into adulthood. The phenotypic spectrum is
therefore much wider, with implications for counseling of pa-
tients and their families.
We attempted to identify clinical, biochemical, genetic and/
or MRI characteristics typical for this subgroup with long
survival. We divided the patients in this cohort into two cate-
gories based on the degree of communication. Patients in
group 1 (patients 1–12) were able to communicate with struc-
tured grammatical speech and patients in group 2 (patients 13–
19) did not achieve structured speech. The correlation be-
tween the phenotype and genotype, at least with respect to
the mild PEX1 c.2528G>A and PEX26 c.292C>T mutation
in its homozygous form versus the more severe compound
heterozygosity (PEX1 c.2097insT+PEX1 c.2528G>A),
which was described previously (Rosewich et al 2005)
(Bader et al 2000), was also seen in our study.
In previous case reports, age at first symptoms varied from
3 to 12 years and age at diagnosis varied from 10 to 51 years
(Rosewich et al 2005) (Mignarri et al 2012) (Matsui et al
2013) (Raas-Rothschild et al 2002) (Régal et al 2010). The
average age at diagnosis in our cohort was at a much earlier
age of 5.2 years. Hence, we had the possibility to monitor the
clinical and biochemical spectrum over a relatively long peri-
od of time.
Hearing impairment, an important characteristic of ZSD
patients (Moser et al 1995), was not reported in some of the
mild adult patients described in previous reports (Régal et al
2010) (Sevin et al 2011) (Steinberg et al 2009), but all patients
in our cohort had impaired hearing and vision. The predomi-
nant neurological symptom in the adult patients is a gait
Table 3 Brain magnetic resonance imaging characteristics in 19 ZSD
patients
Patients no. Age at
MRI, yrs






1 14 ─ ─ ─ ─
21 ─ ─ ─ ─
30 ─ ─ ─ ─
2 32 ─ + + + + ─
3 10 ─ ─ ─ ─
16 + + + ─
25 + + + + + +
4 12 ─ ─ ─ ─
5 7 ─ + + +
13 ─ + + +
21 ─ ++ + ++
6 0.5 ─ ─ ─ ─
2 ─ ─ ─ ─
4 ─ + ─ ─
11 + + + + ─ ─
14 +++ +++ + ─
17 ++++ ++++ ++ ─
18 +++++ +++++ +++ ─
22 +++++ +++++ ++++ ─
7 14 ─ ─ ─ ─
8 4 ─ ─ ─ ─
13 ─ + ─ +
17 ─ + ─ +
9 3 ─ ─ ─ ─
6 ─ ─ ─ ─
13 ++ ++ ++ ─
16 ++ ++ ++ ─
10 none
11 3 ─ ─ ─ ─
15 ─ ─ ─ ─
12 6 ─ + ─ ─
11 ─ + ─ ─
16 ─ + ─ ─
13 none
14 none
15 1 ─ ─ ─ ─
16 7 ─ ─ ─ +
17 7 + + ─ ─
18 1 ─ ─ ─ ─
17 ─ ─ + +
19 3 ─ ─ ─ ─
9 ─ ─ ─ +
Abbreviation: HDN hilus of the dentate nucleus, WM cerebellar white
matter
B−^ = absent; B+^ = The number of plus signs indicates disease severity
a T2-weighted images
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Fig. 1 a–c Growth, development, brain MR images and biochemical
parameters of patient 6. a At the age of 2 and 4 years patient 6 was
completely normal and only presented a mild developmental delay and
visual impairment. Since the age of 16 years, a decline in disease
progression was noted and this patient developed progressive pyramidal
tract symptoms with a gait ataxia. b Leukoencephalopathy with slowly
progressive disease course. Axial T2-weighted MR images at level of
cerebellar dentate nuclei and cerebellar white matter show bilateral
progressive white matter hyperintensities of the hilus of the dentate
nucleus and central white matter of both hemispheres between 4 and
22 years old. MR images at 2 years old were normal. c Fluctuations of
the biochemical parameters measured in plasma at different time points,
which are representative for the other patients. Note that both DHCA and
THCAwere normal at the age of 15 years but abnormal at 21 years. The
reference range of pipecolic acid is 0.1–7 μmol/l, of THCA 0.0–
0.1 μmol/l and of C26:0 0.45–1.32 μmol/l. The levels of DHCA are
not detectable in controls. d Boxplot showing median, interquartile
range, minimal and maximal range of the average level of DHCA,
THCA, C26:0 (all left axis) and pipecolic acid (right axis) in plasma per
patient throughout life between group 1 (white andwhite dotted bars) and
2 (gray and gray dotted bars). A total of 332 biochemical analyses were
performed, ranging from 2 (patient 4) to 43 (patient 18) tests per patient.
Statistical analyses were performed with a Mann–Whitney U test.
Abbreviation: ns, not significant
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disorder, caused by combinations of a cerebellar syndrome,
pyramidal tract dysfunction and peripheral neuropathy.
Unexpectedly, we observed a high prevalence of signs of pe-
ripheral neuropathy in adolescence/adulthood (11/19), espe-
cially in group 2 (6/7), while none of these patients presented
these symptoms in childhood. The majority of patients was
diagnosed with a peripheral neuropathy on clinical grounds.
Confirmatory nerve conduction studies, however, were only
performed in two patients, which is a limitation of our study.
As reported previously (England et al 2005), the combination
of signs and symptoms have a relatively good accuracy for
diagnosing a peripheral neuropathy. It is noteworthy that two
patients developed a demyelinating peripheral neuropathy.
This contrasts with another peroxisomal disease, X-linked ad-
renoleukodystrophy, in which axonal rather than a demyelin-
ating peripheral neuropathy is usually present (van Geel et al
1996) (Engelen et al 2011) (Chaudhry et al 1996).
Previous MRI studies showed progressive cerebral demy-
elination in peroxisome biogenesis disorder patients with a
mild phenotype, mostly in the cerebellum, brainstem, posteri-
or limb of the internal capsule and posterior cerebral white
matter (Barth et al 2004). In this study, the major MRI abnor-
malities (i.e., white matter hyperintensities) were found in the
central white matter of both cerebellar hemispheres and/or
areas surrounding the dentate nuclei on T2-weighted images
(9/16). These lesions can also be found in patients with D-
bifunctional protein deficiency, an isolated peroxisomal β-
oxidation defect, with prolonged survival (i.e., >7.5 years)
(Ferdinandusse et al 2006). Normal MRI was found in five
patients. Symptomatic leukoencephalopathy was present in
seven patients (2, 5–6, 9, 12, 17–18) and silent
leukoencephalopathy in two (3, 8). Overall, individuals in
both groups presented similar findings on MRI ranging from
normal findings to leukoencephalopathy.
Liver dysfunction is a common feature in ZSD patients.
However, in this cohort only four patients (in group 2) had
liver cirrhosis/fibrosis. The prevalence of hyperoxaluria (2/14)
and hyperglycolic aciduria (3/13) was much lower than previ-
ously reported in ZSD patients older than 1 year (vanWoerden
et al 2006). Only patient 18 suffered from nephro- and
urolithiasis.
In our cohort 12 patients were clinically stable in recent
years and seven showed a progressive disease course. The
disease progression becomes apparent in adolescence (age
12–16 years), with gait disturbance being the most prominent
symptom (in 7/7).
Seventeen of the 19 patients had a typical ZSD biochemical
phenotype in blood at the time at diagnosis. At latest follow-
up we observed normal blood levels of several peroxisomal
biomarkers in patients (Table 4). Normal levels of some pa-
rameters have already been reported by others (Sevin et al
2011) (Ebberink et al 2010). Importantly, our study is the first
to show a decline in the levels of these metabolites with age
and in some patients even a complete normalization. In par-
ticular the levels of DHCA, THCA, and pipecolic acid were
found to decline during life and they eventually normalized. In
some patients we noted a decrease in these parameters as well
as in liver enzymes. This suggests that improved liver function
might play a role in the decrease of these metabolites, as they
are predominantly synthesized in the liver (Ferdinandusse and
Houten 2006). However, there were also patients with normal
liver function and elevated levels of abnormal peroxisomal
metabolites in childhood. In these patients we also observed
a decline in these peroxisomal parameters, meaning that this
decline cannot be entirely attributed to normalization of liver
functions. The decline in DHCA and THCA levels may also
be caused by a decreased synthesis of bile acids with increas-
ing age (Einarsson et al 1985). Furthermore, we observed
strong fluctuation of several parameters in the majority of
the patients. The concentration of peroxisomal metabolites
can fluctuate between normal and abnormal (Fig. 1).
Overall, the diagnosis ZSD would be missed in two patients
(2 and 11) at last follow-up and in patient 4 at first analysis
based on the C26:0, bile acid levels, pristanic- and phytanic
acid concentrations in plasma.
Our data suggest that a ZSD cannot be excluded by bio-
chemical testing in plasma alone, and that in some individuals
(i.e., patient 2, 4, and 11) a complete analysis in skin fibro-
blasts (including culturing fibroblasts at 40 °C (Ebberink et al
2012)) is indicated if clinical suspicion is high. Skin fibroblast
examination is also necessary to discriminate between a ZSD
or a single-enzyme deficiency, which is diagnosed in at least
15 % of the individuals presenting with a ZSD clinical phe-
notype (Steinberg et al 2003). Recently, D-bifunctional pro-
tein-deficiency has been identified by whole-exome sequenc-
ing in seven adults without detectable biochemical abnormal-
ities in blood (Pierce et al 2010) (McMillan et al 2012) (Lines
et al 2014). Because of considerable overlap between Usher
syndrome and milder ZSD phenotypes, i.e., the combination
of deafness and retinitis pigmentosa, individuals suspected to
have Usher syndrome should be screened for peroxisomal
dysfunction (Raas-Rothschild et al 2002).
Efforts to correlate biochemical, cellular, and molec-
ular characteristics of ZSD patients to their clinical out-
come, mainly in terms of survival, have provided valu-
able information. Gootjes et al suggested that DHAPAT
and C26:0 β-oxidation activity are predictors of survival
in patients with a ZSD. However, these measurements
in cultured skin fibroblasts could only be used to rough-
ly predict survival of <1 year or >5 years (Gootjes et al
2002). Despite these associations, prediction of progno-
sis remains challenging and is influenced by many other
variables (e.g., quality of supportive care). We evaluated
how the parameters of peroxisomal dysfunction relate to
disease severity and long-term progression. We noticed
higher levels of abnormal peroxisomal metabolites (e.g.,
104 J Inherit Metab Dis (2016) 39:93–106
DHCA, THCA, and C26:0) in group 2 during child-
hood, but there were no differences in adulthood.
Concentrations of pipecolic acid were higher in those
patients with a progressive disease course. Patients in
group 2 had higher levels of C26:0 in plasma than patients
in group 1 throughout life (Fig. 1d). Ferdinandusse et al re-
ported that C27-bile acid intermediates (DHCA/THCA) in-
duce apoptosis, decrease cell viability and are more toxic than
C24-bile acids (Ferdinandusse et al 2009). It is noteworthy
that the most severely affected patient (18) had extremely
high plasma levels of DHCA and THCA ranging from 50
to 130 μmol/l in the first year of life. The patients with a
less severe phenotype presented with DHCA and THCA
levels of approximately 10 and 2 μmol/l, respectively.
However, on the basis of the present study, we were un-
able to identify a correlation between the concentration of
abnormal peroxisomal metabolites, skin fibroblast data
and the severity of the clinical phenotype or progression
of the disease. The metabolites measured in plasma prob-
ably do not reflect the level of accumulation in organs.
This suggests that the wide spectrum of clinical presenta-
tions may be related to varying amounts of residual per-
oxisomal enzymatic activities in target tissue. Further
studies are therefore required to determine the precise role
of the peroxisomal biomarkers in the pathogenesis of
ZSDs. The recently constructed PEX1 mouse model
(Hiebler et al 2014) may be a valid model to study these
relations.
In summary, we describe the natural history of a cohort of
ZSD patients who reached adulthood and represent a distinct
subgroup within the ZSDs. A high percentage of patients
show pyramidal symptoms with or without peripheral neurop-
athy. Some patients with prolonged survival present an insid-
iously progressive disease course, despite normalization of
biomarkers for peroxisomal disease measured in plasma and
erythrocytes. This study emphasizes that ZSDs should no lon-
ger be considered solely as a paediatric disease, but rather as a
slowly progressive disease with patients surviving into adult-
hood. This study is important for the interpretation of future
therapeutic trials and for those involved in the clinical care of
adult patients.
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